Authoritative recognition! Sihuan Pharmaceuticals continues to be included in S&P’s 2026 Sustainability Yearbook (China Edition).

Authoritative recognition! Sihuan Pharmaceuticals continues to be included in S&P’s 2026 Sustainability Yearbook (China Edition).

Huisheng Biopharmaceutical and Tonghua Dongbao Achieve Exclusive Commercial Cooperation; Two Main Insulin Products Accelerate Nationwide Market Expansion

Huisheng Biopharmaceutical and Tonghua Dongbao Achieve Exclusive Commercial Cooperation; Two Main Insulin Products Accelerate Nationwide Market Expansion

Declaration

Sihuan Metformin Hydrochloride Tablet Passes Consistency Evaluation

The product’s successful passing the consistency evaluation is the authoritative recognition of Sihuan's R&D capability, production and product quality and product efficacy, and also gives it an advantage in future market access, medical insurance payment and other areas.

Sihuan Officially Starts Phase II Clinical Trial on Pirotinib in China

Sihuan Pharmaceutical Holdings Group Co., Ltd. (HKEx stock code 00460), a cardio-cerebral vascular drug manufacturer in the Chinese prescription drug market, announces that, Pirotinib, an innovative anti-tumor drug independently developed by it, has completed Phase I clinical trial in the United States and officially started Phase II clinical trial in China

Che Fengsheng and His Team Visit Jiulongpo Hospital 2 for Work Guidance

On June 24, 2018, Che Fengsheng, Chairman of the Board of Directors and President of the Group, Wang Xin, Secretary of the Party Committee of Zhongshan Hospital of Fudan University, Gao Fabao, Professor of West China Hospital of Sichuan University, and other experts, accompanied by Li Hongliang, Deputy Head of Jiulongpo District, Chongqing, visited the Second People's Hospital of Jiulongpo District, Chongqing (Jiulongpo Hospital 2) for work guidance. Jia Fei, Director of Government Office of the